ArticleScientific reports2023
Cold atmospheric plasma treatment enhances recombinant model protein production in yeast Pichia pastoris.
Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A dual-index framework for cold atmospheric plasma dosing: A meta-analysis of parametric control from volumetric redox flux to redox homeostatic status.Redox biology · 2026Pooled it
- Targeting and monitoring cancer cells with cold atmospheric plasma and PET Imaging: a new theranostic approach.Medical oncology (Northwood, London, England) · 2026Article
- Enhancing recombinant thaumatin production by Komagataella phaffii through cold atmospheric helium plasma jet.Scientific reports · 2025Article
- Article
- Promoters in Pichia pastoris: A Toolbox for Fine-Tuned Gene Expression.Methods in molecular biology (Clifton, N.J.) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cold atmospheric pressure plasma (CAP) has been described as a novel technology with expanding applications in biomedicine and biotechnology. In the present study, we provide a mildly stressful condition using non-lethal doses of CAP (120, 180, and 240 s) and evaluate its potential benefits on the recombinant production of a model protein (enhanced green fluorescent protein (eGFP)) in yeast Pichia pastoris. The measured eGFP fluorescence augmented proportional to CAP exposure time. After 240 s treatment with CAP, the measured fluorescent intensity of culture supernatant (after 72 h) and results of real-time PCR (after 24 h) indicated an 84% and 76% increase in activity and related RNA concentration, respectively. Real-time analysis of a list of genes involved in oxidative stress response revealed a significant and durable improvement in their expression at five h and 24 h following CAP exposure. The improvement of the recombinant model protein production may be partly explained by the impact of the RONS on cellular constituents and altering the expression of specific stress genes. In conclusion, using CAP strategy may be considered a valuable strategy to improve recombinant protein production, and deciphering the molecular background mechanism could be inspiring in the reverse metabolic engineering of host cells.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.